» Articles » PMID: 15234806

Comparative Study of Influenza Virus Replication in Vero and MDCK Cell Lines

Overview
Journal J Virol Methods
Specialty Microbiology
Date 2004 Jul 6
PMID 15234806
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The choice of a cell line for the production of influenza vaccines is determined by how well the virus is able to replicate and how easily the cell line can be maintained. Madin-Darby canine kidney (MDCK) cells have long been known to successfully support influenza growth. Vero cells are also another well studied candidate cell line. In this work, we have compared these two cell lines for their ability to propagate type A and type B cold-adapted and wild type influenza viruses. The growth of these viruses has been measured as plaque forming units (via plaque assay) as well as viral particle formation (via a novel quantitative RT-PCR assay) to assess the suitability of these cell lines to support the development of live attenuated influenza vaccines. The novel qRT-PCR assay outlined in this work was demonstrated to be an efficient, sensitive and reproducible method for measuring wild type (wt) and cold-adapted (ca) influenza strains. Replicates of six per sample consistently showed an average variation around +/-10%. In this study we have also found qRT-PCR to be a useful method for differentiating between wt and ca influenza strains based on their differing growth characteristics at varying temperatures. This can subsequently be used to assess reassortants prepared from ca donor strains for the purposes of live viral vaccine development. For type A and B influenza viruses studied in this work, MDCK cells supported a more rapid viral growth (measured in terms of genome copies) compared with Vero cells. For the type A viruses studied here, the genome copies: infectious unit (genome copy, gc:infectious unit, iu) ratio was found to be more favorable for Vero cells compared with MDCK cells. For the type B viruses studied in this work, the gc:iu was equivalent in both cell lines tested. Ultimately, however, the use of any new cell line would need to be approved by regulatory agencies prior to its commercial application.

Citing Articles

In Vitro Anti-Influenza A Virus H1N1 Effect of Sesquiterpene-Rich Extracts of .

Li L, Yang S, Chen D, Wu Z, Zhang M, Yang F Molecules. 2022; 27(23).

PMID: 36500406 PMC: 9739900. DOI: 10.3390/molecules27238313.


Cell-Adapted Mutations and Antigenic Diversity of Influenza B Viruses in Missouri, 2019-2020 Season.

Tang C, Segovia K, McElroy J, Li T, Guan M, Zhang X Viruses. 2021; 13(10).

PMID: 34696325 PMC: 8538563. DOI: 10.3390/v13101896.


Identification of One Critical Amino Acid Residue of the Nucleoprotein as a Determinant for Replication Fitness of Influenza D Virus.

Yu J, Huang C, Sheng Z, Wang Z, Li F, Wang D J Virol. 2021; 95(18):e0097121.

PMID: 34190601 PMC: 8387045. DOI: 10.1128/JVI.00971-21.


High cell density perfusion process for high yield of influenza A virus production using MDCK suspension cells.

Wu Y, Bissinger T, Genzel Y, Liu X, Reichl U, Tan W Appl Microbiol Biotechnol. 2021; 105(4):1421-1434.

PMID: 33515287 PMC: 7847233. DOI: 10.1007/s00253-020-11050-8.


Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells.

Boltz D, Peng X, Muzzio M, Dash P, Thomas P, Margitich V Antivir Chem Chemother. 2018; 26:2040206618811416.

PMID: 30466301 PMC: 6961345. DOI: 10.1177/2040206618811416.